Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
NCT03276481 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47
Last updated 2023-07-14
Summary
The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Oral microbiota assessment
Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
- DIAGNOSTIC_TEST
-
Comprehensive chemical gustometry
Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
- DIAGNOSTIC_TEST
-
Measurement of salivary flow
Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
- BEHAVIORAL
-
Surveys assessing taste disturbances
Surveys will be administered and examine taste disturbances pre and post HCT.
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Sergio Giralt, MD · Memorial Sloan Kettering Cancer Center
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-08-28
- Primary Completion
- 2023-07-12
- Completion
- 2023-07-12
Countries
- United States
Study Locations
More Related Trials
-
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT03346135 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
NCT00112827 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
NCT05013437 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
NCT01114048 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
NCT02331368 ·Status: COMPLETED ·Phase: PHASE2
-
Personalized Autologous Transplant for Multiple Myeloma
NCT04483206 ·Status: RECRUITING ·Phase: PHASE1
-
Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation
NCT03508765 ·Status: COMPLETED ·Phase: NA
-
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05855122 ·Status: UNKNOWN ·Phase: PHASE4
-
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 ·Status: RECRUITING
-
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
NCT01045460 ·Status: COMPLETED ·Phase: PHASE2
-
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01816971 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
NCT00003153 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
NCT03328936 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
NCT00325416 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
NCT01690143 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT02353572 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
NCT04497961 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
NCT00434161 ·Status: COMPLETED ·Phase: PHASE3
-
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
NCT00702247 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
NCT02504359 ·Status: COMPLETED ·Phase: PHASE1
-
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
NCT00793650 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01251172 ·Status: WITHDRAWN ·Phase: PHASE2
-
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
NCT00205764 ·Status: COMPLETED ·Phase: PHASE3
-
Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients
NCT00950768 ·Status: COMPLETED ·Phase: PHASE3
-
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
NCT00619684 ·Status: COMPLETED ·Phase: PHASE2